

Electromedical Technologies, Inc.

10105 E. Via Linda #103-300
Scottsdale, AZ 85258

+1 888-880-7888
electromedtech.com
ir@electromedtech.com
SIC Code: 3841 (Primary)

Quarterly Report

For the period ending March 31, 2026 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

3,732,294,292 as of March 31, 2026

3,732,294,292 as of December 31,

2025

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

"Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities.
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Current name of the issuer: Electromedical Technologies Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The issuer is incorporated and active and in good standing in the State of Delaware.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

10105 E. Via Linda #103-300
Scottsdale, AZ 85258

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Pacific Stock Transfer
Phone: +1 800-785-7782
Email: info@securitize.io
Address: 6725 Via Austi Pkwy #300, Las Vegas, NV 89119, United States

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	EMED
Exact title and class of securities outstanding:	Common Stock
CUSIP:	28540Q100
Par or stated value:	\$0.00001
Total shares authorized:	5,000,000,000 as of date: March 31, 2026
Total shares outstanding:	3,732,294,292 as of date: March 31, 2026
Total number of shareholders of record:	109 as of date: March 31, 2026

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Series A Preferred
CUSIP (if applicable):	28540Q100
Par or stated value:	\$0.00001
Total shares authorized:	1,000,000 as of date: March 31, 2026
Total shares outstanding (if applicable):	1,000,000 as of date: March 31, 2026
Total number of shareholders of record	1 as of date: March 31, 2026

Exact title and class of the security:	Series B Preferred
CUSIP (if applicable):	28540Q100
Par or stated value:	\$0.00001
Total shares authorized:	1 as of date: March 31, 2026
Total shares outstanding (if applicable):	1 as of date: March 31, 2026
Total number of shareholders of record	1 as of date: March 31, 2026

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Common Stock: Holders of shares of common stock are entitled to share ratably in dividends, if any, as may be declared, from time to time, by the Board of Directors in its discretion, from funds legally available, therefore. The Company does not currently anticipate paying any dividends on its common stock. In the event of a liquidation, dissolution or winding up of the Company, the holders of shares of common stock are entitled to share pro rata all assets remaining after payment in full of all liabilities. Holders of common stock have no preemptive rights to purchase the Company's common stock. There are no conversion rights or redemption or sinking fund provisions with respect to the common stock. All of the outstanding shares of common stock are fully paid and non-assessable.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Preferred Stock: Series A Preferred with a par value of \$0.00001 per share. Holders of Series A Convertible Preferred Stock hold rights to vote on all matters requiring a shareholder vote at 100 common shares vote equivalent for each share of Series A Preferred Stock held.

Series B Preferred Stock: The Series B Preferred Stock shall rank senior to all of the Common Stock, par value \$0.00001 per share, of the Company and senior to all other classes or series of capital stock of the Company currently outstanding.

The Holder of the Series B Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Company's Common Stock, and on all such matters, the share of Series B Preferred Stock shall be entitled to that number of votes equal to the total number of eligible votes of issued and outstanding shares

of Common Stock, and all other securities of the Company, plus one hundred thousand (100,000) votes on a fully diluted basis, it being the intention of the Company that the Holder of the Series B Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder of the Series B Preferred Stock shall vote together with the holders of Common Stock as a single class.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

N/A

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding Fiscal Year End:		as of Second Most Recent		*Right-click the rows below and select "Insert" to add rows as needed.					
Date: 12/31/2023		Opening Balance							
		Common: 463,286,208							
		Preferred A: 1,000,000							
		Preferred B: 1							
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
3/26/24	New Issuance	23,196,579	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/30/24	New Issuance	20,805,607	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
5/7/24	New Issuance	25,392,288	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
5/24/24	New Issuance	4,019,480	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144

6/3/24	New Issuance	26,859,935	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
6/6/24	New Issuance	2,551,833	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
7/1/24	New Issuance	28,327,582	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
8/2/24	New Issuance	29,411,764	Common	\$0.00102	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
8/13/24	New Issuance	26,500,000	Common	\$0.0014	Yes	Jefferson Street Capital, LLC – Brian Goldberg	Conversion of Debt	Unrestricted	Rule 144
9/3/24	New Issuance	29,411,764	Common	\$0.0008	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
9/24/24	New Issuance	30,588,236	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
9/24/24	New Issuance	15,000,000	Common	\$0.0005	No	PCG Advisory, Inc - Jeff Ramson	Consulting Services	Restricted	Rule 144
10/1/24	New Issuance	36,223,726	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
10/2/24	New Issuance	23,776,280	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
10/23/24	New Issuance	693,500	Common	\$0.0004	No	Lee Benson	Settlement	Restricted	Rule 144
10/24/24	New Issuance	39,000,000	Common	\$0.0004	No	Matthew Wolfson	Executive Compensation	Restricted	Rule 144
10/24/24	Return to Treasury	-5,690	Common	\$0.0001	No	Tina Ingram	Settlement	Restricted	Rule 144
11/1/24	New Issuance	41,208,640	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
11/14/24	New Issuance	18,791,360	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
12/2/24	New Issuance	44,202,640	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
12/6/24	New Issuance	15,797,360	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/2/25	New Issuance	47,196,640	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/3/25	New Issuance	47,196,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/7/25	New Issuance	51,906,800	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144

1/10/25	New Issuance	54,496,900	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/15/25	New Issuance	57,216,300	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/16/25	New Issuance	60,071,400	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/17/25	New Issuance	63,069,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
1/30/25	New Issuance	66,216,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
2/11/25	New Issuance	69,520,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
2/27/25	New Issuance	72,989,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
3/6/25	New Issuance	76,631,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
3/19/25	New Issuance	80,455,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/8/25	New Issuance	84,470,000	Common	\$0.0005	Yes	Mast Hill Fund [P - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/8/25	Reconciliation	785,360	Common	N/A	No	Various shareholders per Transfer Agent	Reconciling Adjustment per Transfer Agent	Restricted	Rule 144
4/10/25	New Issuance	88,680,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/11/25	New Issuance	88,685,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/14/25	New Issuance	97,530,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/15/25	New Issuance	102,400,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 144
4/16/25	New Issuance	102,402,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/17/25	New Issuance	112,600,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/21/25	New Issuance	118,200,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/23/25	New Issuance	98,000,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)

4/24/25	New Issuance	129,000,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/28/25	New Issuance	135,000,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/29/25	New Issuance	142,000,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
4/30/25	New Issuance	53,843,380	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
5/1/25	New Issuance	43,824,580	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
5/1/25	New Issuance	89,370,840	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
6/4/25	New Issuance	160,500,000	Common	\$0.0005	Yes	Mast Hill Fund LP - Patrick Hassani	Conversion of Debt	Unrestricted	Rule 4(a)(1)
7/2/25	New Issuance	50,000,000	Common	\$0.0005	Yes	Jefferson Street Capital, LLC – Brian Goldberg	Conversion of Debt	Unrestricted	Rule 4(a)(1)
7/8/25	New Issuance	166,000,000	Common	\$0.0005	Yes	Pinnacle Consulting Services, Inc. - Robert L. Hymers III	Conversion of Debt	Unrestricted	Rule 4(a)(1)
9/2/25	New Issuance	177,000,000	Common	\$0.0005	Yes	Pinnacle Consulting Services, Inc. - Robert Hymers III	Conversion of Debt	Unrestricted	Rule 4(a)(1)

Shares Outstanding on Date of This Report:		
<u>Ending Balance:</u>		
Date 5/20/2026	Common: 3,732,294,292	
	Preferred A: 1,000,000	
	Preferred B: 1	

Example: A company with a fiscal year end of December 31st, 2025, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2024, through December 31, 2025, pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

N/A

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be	Name of Noteholder. *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
03/10/22	\$307,500	\$342,472	09/25/25	\$.0005/share	36,600,000	684,944,000	Blue Lake Fund/Craig Kesselman	Loan
08/08/22	\$176,000	\$48,750	05/08/23	\$.0001/share	91,934,171	487,500,000	Jefferson Street Capital LLC/Brian Goldberg	Loan
Unknown	\$50,000	—	Unknown	Unknown	—	Unknown	Michelle Lu	Loan
06/16/25	\$40,000	\$5,700	—	\$.0005/share	343,000,000	11,400,000	Pinnacle Consulting Services – Robert Hymers	Loan
06/04/25	\$35,000	\$35,000	12/04/25	conversion price equal to sixty percent (60%) of the lowest closing bid price of the Company's common stock during the five (5) trading days immediately preceding the applicable date of conversion	—	583,333,333	Pinnacle Consulting Services – Robert Hymers	Loan
06/18/25	\$30,000	\$30,000	12/18/25	conversion price equal to sixty percent (60%) of the lowest closing bid price of the Company's common stock during the five (5) trading days immediately preceding the applicable date of conversion	—	500,000,000	Pinnacle Consulting Services – Robert Hymers	Loan
7/3/2025	\$32,000	\$32,000	1/3/2026	conversion price equal to sixty percent (60%) of the lowest closing bid price of the Company's common stock during the five (5) trading days immediately preceding the applicable date of conversion	—	533,333,333	Pinnacle Consulting Services – Robert Hymers	Loan
7/10/2025	\$21,000	\$21,000	1/10/2026	conversion price equal to sixty percent (60%) of the lowest closing bid price of the Company's common stock during the five (5) trading days immediately preceding the applicable date of conversion	—	350,000,000	Pinnacle Consulting Services – Robert Hymers	Loan

Total Outstanding Balance:	\$514,922	Total Shares:	471,534,171	3,150,510,666
-----------------------------------	-----------	----------------------	-------------	---------------

Any additional material details, including footnotes to the table are below:

Pinnacle Consulting Services acquired \$40,000 of the Jefferson Street Note on June 16, 2025

Conversion shares are for principal only

4) Issuer's Business, Products and Services

Electromedical Technologies, Inc. is a Delaware-based public company specializing in **bioelectronics**—a rapidly emerging field of "electronic medicine" focused on using electrical impulses to interact with the nervous system to manage pain. The company designs, manufactures, and markets **FDA-cleared, non-invasive medical devices** that serve as **drug-free alternatives** for pain relief. Its core mission is to improve global wellness by offering safe and effective solutions for chronic and acute pain, helping patients avoid opioid-based treatments.

The company's technology leverages the human body's natural electrical communication systems. By delivering proprietary electrical signals through bioelectronic devices, Electromedical Technologies aims to **restore balance in neural circuitry** and alleviate conditions like arthritis, fibromyalgia, chronic back pain, neuropathy, and more.

Flagship Products

1. WellnessPro Plus[®]

- A prescription-grade bioelectronic therapy device.
- FDA-cleared as a TENS (Transcutaneous Electrical Nerve Stimulation) device.
- Enhanced with **DeepPulse™** technology for dynamic frequency variation, reducing treatment resistance.

2. WellnessPro Infinity™

- A next-generation evolution of the WellnessPro Plus.
- Offers **expanded therapeutic modalities**, microcurrent capabilities, and advanced precision features.
- Designed to serve as the **core platform** for a suite of future devices.
- The WellnessPro Infinity™ has been completed with launch anticipated in April 2026.

3. WellnessPro GO™ (launching Q1 2027)

- A **wearable, over-the-counter** clinical-grade device.
- Targets chronic pain, PTSD, anxiety, depression, and insomnia.
- Can operate independently or integrate with the Infinity platform.

4. Wellness ION Pen™

- A **handheld interferential cold laser** for targeted frequency stimulation.
- Intended for pain relief, tissue healing, and cosmetic skin treatments.
- The Wellness ION Pen™ is no longer in development as management believes it is no longer needed to complement its suite of products.

Target Markets

- Chronic pain patients (over 100 million in the U.S. alone) (Institute of Medicine. (2011). *Relieving pain in America: A blueprint for transforming prevention, care, education, and research*. National Academies Press)
- U.S. veterans (22 million individuals) (*U.S. Department of Veterans Affairs, 2016*)
- Chiropractors, physical therapists, sports medicine professionals, and pain clinics.

Regulatory and Industry Standing

The company's devices are FDA-cleared under the 510(k) regulatory pathway, with quality control and labelling managed per FDA's Quality System Regulation (QSR). Internationally, the company plans to seek a CE Mark certification for broader global distribution sometime in late 2026. Electromedical is publicly traded on the OTC Markets under the symbol **EMED**.

Strategic Focus

With a strong emphasis on addressing the opioid crisis, the company is focused on providing effective alternatives to addictive medications through **safe, scalable, and innovative** technologies. It aims to expand its digital health ecosystem, leverage AI-powered outreach, and establish strong community-led and clinical advocacy programs.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

In September 2023, the Company entered into an operating lease for its office location. The lease provided for a base rent of \$6,500 per month through 2025, but the Company did not renew the lease as of July 1, 2025, and now has no office location and is working remotely until another location is found suitable for storage of its inventory.

The Company uses a contract manufacturer in Sofia, Bulgaria to manufacture its products.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Matthew Wolfson	CEO, CFO, Director	7460, E Tuckey Ln Scottsdale, AZ 85250	54,406,250	Common shares	1.45%
Matthew Wolfson	CEO, CFO, Director	7460, E Tuckey Ln Scottsdale, AZ 85250	1,000,000	Series A preferred stock	100%
Matthew Wolfson	CEO, CFO, Director	7460, E Tuckey Ln Scottsdale, AZ 85250	1	Series B preferred stock	100%
Petar Gajic	Director	Scottsdale, Arizona	500,000	Common shares	0.01%

3) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding, and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

8) Third Party Service Providers

Provide the name, address, telephone number, and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Stephen Boatwright
Firm: Gallagher & Kennedy
Address 1: 2575 E Camelback Rd., Suite 1100
Address 2: Phoenix, AZ 85016
Phone: 602-530-8000
Email: steve.boatwright@gknet.com

Accountant or Auditor

Name: Matthew Wolfson
Electromedical Technologies, Inc. CFO
10105 E. Via Linda #103-300
Scottsdale, AZ 85258

All other means of Investor Communication:

X (Twitter): n/a
Discord: _____
LinkedIn Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: n/a
Firm:
Nature of Services:
Address 1:
Address 2:
Phone:
[Email:](#)

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Matthew Wolfson
Title: CFO
Relationship to Issuer: CEO and CFO

B. The following financial statements were prepared in accordance with:

- IFRS
- U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Matthew Wolfson
Title: CFO
Relationship to Issuer: CEO and CFO

Describe the qualifications of the person or persons who prepared the financial statements:⁶ 20 years of corporate finance and accounting experience.

Provide the following qualifying financial statements:

- o Audit letter, if audited;
- o Balance Sheet;
- o Statement of Income;
- o Statement of Cash Flows;
- o Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- o Financial Notes

The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Matthew Wolfson certify that:

1. I have reviewed this Disclosure Statement for Electromedical Technologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 20, 2026

/s/ Matthew Wolfson

Principal Financial Officer:

I, Matthew Wolfson certify that:

1. I have reviewed this Disclosure Statement for Electromedical Technologies, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 20, 2026

/s/ Matthew Wolfson

ELECTROMEDICAL TECHNOLOGIES, INC.
BALANCE SHEETS

(UNAUDITED)

	March 31, 2026	December 31,
ASSETS		
Current assets:		
Cash and cash equivalents	\$92,152	\$435,600
Accounts receivable	\$11,520	\$11,615
Inventories	\$21,059	\$21,059
Prepaid inventories and other current assets	\$402,032	\$242,558
Total current assets	\$526,763	\$710,832
Property and equipment, net	\$149,705	\$149,705
Total assets	\$676,468	\$860,537
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable	\$547,942	\$535,603
Credit cards payable	\$9,460	\$34,810
Accrued expenses and other current liabilities	\$1,165,133	\$995,708
Customer deposits	\$1,273,427	\$1,264,060
Convertible promissory notes, net of discount of \$0	\$514,923	\$514,923
Loan payable	\$500,000	\$500,000
Long term debt, current portion	\$40,121	\$40,930
Derivative liabilities	\$442,430	\$442,430
Total current liabilities	\$4,493,436	\$4,328,464
Government debt, net of current portion	\$150,009	\$150,009
Other liabilities	\$-	\$74
Total liabilities	\$4,643,445	\$4,478,547
Commitments and contingencies (Note 11)	—	—
Stockholders' deficit		
Series A Preferred Stock, 1,000,000 shares authorized and outstanding	365,000	365,000
Series B Preferred Stock, 1 share authorized and outstanding	400,000	400,000
Common stock, \$.00001 par value, 5,000,000,000 shares authorized; 3,732,294,292 shares outstanding at March 31, 2026, and December 31, 2025	37,322	37,322
Additional paid-in-capital	\$25,781,223	\$25,781,223
Accumulated deficit	\$(30,550,522)	\$(30,201,555)
Total stockholders' deficit	\$(3,966,977)	\$(3,618,010)
Total liabilities and stockholders' deficit	\$676,468	\$860,537

The accompanying notes are an integral part of these financial statements

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENTS OF OPERATIONS

(UNAUDITED)

THREE MONTHS ENDED MARCH 31,

	2026	2025
Net sales	\$3,849	\$14,519
Cost of sales	\$(505)	\$3,733
Gross profit	\$4,354	\$10,786
Selling, general and administrative expenses	\$234,610	\$264,978
Loss from operations	\$(230,256)	\$(254,192)
Other income (expense)		
Interest expense	\$(118,711)	\$(37,744)
Total other expense	\$(118,711)	\$(291,936)
Net loss	\$(348,967)	\$(291,936)
Net loss attributable to common stockholders	\$(348,967)	\$(291,936)
Weighted average shares outstanding - basic and diluted	2,926,606,731	1,428,835,569
Weighted average loss per share - basic and diluted	\$(0.00)	\$(0.00)

The accompanying notes are an integral part of these financial statements

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENTS OF STOCKHOLDERS' DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2026

(UNAUDITED)

	Series A Preferred Stock		Series B Preferred Stock		Common Stock		Additional Paid in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Amount	Shares	Amount	Shares	Amount	Shares			
Balance, December 31, 2025	\$365,000	1,000,000	\$400,000	1	\$37,322	3,732,294,292	\$25,781,223	\$(30,201,555)	\$(3,618,010)
Net Loss	—	—	—	—	—	—	—	(348,967)	(348,967)
Balance, March 31, 2026	\$365,000	1,000,000	\$400,000	1	\$37,322	3,732,294,292	\$25,781,223	\$(30,550,522)	\$(3,966,977)

The accompanying notes are an integral part of these financial statements

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENT OF STOCKHOLDERS' DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2025
(UNAUDITED)

	Series A Preferred Stock		Series B Preferred Stock		Common Stock		Paid in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Amount	Shares	Amount	Shares	Amount	Shares			
Balance, December 31, 2024	\$ 365,000	1,000,000	\$ 400,000	1	\$ 9,449	945,039,092	\$ 24,148,276	\$ (28,761,684)	\$ (3,838,959)
Conversion of convertible promissory notes	—	—	—	—	7,470	746,964,040	366,012	—	373,482
Net loss	—	—	—	—	—	—	—	(291,936)	(291,936)
Balance, March 31, 2025	\$ 365,000	1,000,000	\$ 400,000	1	\$ 16,919	1,692,003,132	\$ 25,514,288	\$ (29,053,620)	\$ (3,757,413)

The accompanying notes are an integral part of these financial statements

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31,
(UNAUDITED)

	2026	2025
Cash flows from operating activities:		
Net loss	\$(348,967)	\$(291,936)
Adjustments to reconcile net loss to net cash used in operating activities:		
Amortization of right of use asset	---	13,803
Change in operating assets and liabilities:		
Accounts receivable	95	(770)
Inventories	----	2,894
Prepaid expenses and other current assets	(159,474)	(1,790)
Accounts payable	12,339	42,788
Credit cards payable	(25,350)	---
Accrued expenses and other current liabilities	169,351	163,027
Customer deposits	9,367	87,503
Lease liability	---	(13,529)
Other liabilities	---	(924)
Net cash used in operating activities	(342,639)	346
Cash flows from investing activities:		
Purchase of property and equipment	—	—
Sale of property and equipment	—	—
Net cash provided by investing activities	—	—
Cash flows from financing activities:		
Repayments on long-term debt	(809)	(10,522)
Net cash provided by financing activities	(809)	(10,522)
Net increase (decrease) in cash and cash equivalents	(343,448)	(10,176)
Cash and cash equivalents, beginning of year	\$435,600	\$(10,176)
Cash and cash equivalents, end of period	\$92,152	\$---
Supplemental disclosures of cash flow information:		
Cash paid during the year for:		
Interest	\$6,613	\$15,611
Income taxes	—	—
Non-cash investing and financing activities:		
Conversion of convertible promissory notes, derivatives and accrued interest into shares of common	\$----	\$373,482

The accompanying notes are an integral part of these financial statements

ELECTROMEDICAL TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

Electromedical Technologies, LLC (“the Company”), was formed in November 2010 as an Arizona limited liability company. In August 2017, the Company converted to a Delaware C Corporation under Electromedical Technologies, Inc. The Company is a bioelectronic engineering company with medical device certifications in the United States (FDA) and Mexico (Cofepris). The Company engineers simple-to-use portable bioelectronics devices, which provide fast and long-lasting pain relief across a broad range of ailments.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Method

The Company maintains its accounting records on an accrual method in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities, certain disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates affecting the financial statements have been prepared on the basis of the most current and best available information. However, actual results from the resolution of such estimates and assumptions may vary from those used in the preparation of the financial statements.

Going Concern

Since inception, the Company has incurred approximately \$26.8 million of accumulated net losses. In addition, during the three months ended 2026, the Company had a working capital deficit of \$3,966,673. These factors, among others, raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company expects to obtain funding through additional debt and equity placement offerings until it consistently achieves positive cash flows from operations. If the Company is unable to obtain additional funding, it may not be able to meet all of its obligations as they come due for the next twelve months. The continuing viability of the entity and its ability to continue as a going concern is dependent upon the entity being successful in its continuing efforts in growing its revenue base and/or accessing additional sources of capital, and/or selling assets.

As a result, there is significant uncertainty whether the entity will continue as a going concern and, therefore, whether it will realize its assets and settle its liabilities and commitments in the normal course of business and at the amounts stated in the financial statements. Accordingly, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or the amount and classification of liabilities that might be necessary should the entity not continue as a going concern. At this time, management is of the opinion that no asset is likely to be realized for an amount less than the amount at which it is recorded in the financial statements as at March 31, 2026.

Revenue Recognition

Revenues are recognized in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, when performance obligations are satisfied through the transfer of promised goods to the Company’s customers. Control transfers upon shipment of product and when the title has been passed to the customers. This includes the transfer of legal title, physical possession, the risks and rewards of ownership, and customer acceptance. Revenue is recorded net of sales taxes collected from customers on behalf of taxing authorities, allowance for estimated returns, chargebacks, and markdowns based upon management’s estimates and the Company’s historical experience. The Company’s liability for sales return refunds is recognized within other current liabilities, and an asset for the value of inventory which is expected to be returned is recognized within other current assets on the balance sheets. The Company generally allows a 30-day right of return to its customers. As of both March 31, 2026, and December 31, 2025, the sales returns allowance was \$0.

Certain larger customers pay in advance for future shipments. These advance payments totaled \$1,273,427 and \$1,264,060 at March 31, 2026, and December 31, 2025, respectively, and are recorded as customer deposits in the accompanying balance sheets. Revenue related to these advance payments is recognized upon shipment to the distributor or the end-customer.

At the completion of the initial three-year warranty, the Company sells extended warranties for periods ranging from one to three years. Revenue is recognized on a straight-line basis over the term of the contract. At March 31, 2026, and December 31, 2025, deferred revenue of \$1,201 and \$2,126 is recorded, respectively, in current and long-term liabilities in the accompanying balance

sheets, in connection with these extended warranties.

Financial Instruments and Concentrations of Business and Credit Risk

The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk.

The Company's accounts receivable, which are unsecured, expose the Company to credit risks such as collectability and business risks such as customer concentration. The Company mitigates credit risk by investigating the creditworthiness of all customers prior to establishing relationships with them, performing periodic review of the credit activities of those customers during the course of the business relationship, regularly analyzing the collectability of accounts receivables, and recording allowances for doubtful accounts when these receivables become uncollectible. The Company mitigates business risks by attempting to diversify its customer base.

Significant customer sales greater than 10% as a percentage of total sales are as follows:

	<u>THREE MONTHS ENDED MARCH 31,</u>	
	<u>2026</u>	<u>2025</u>
Customer A	24%	21.0%
Customer D	0.0%	19.0%

Amounts due to these customers totaled \$42 at March 31, 2026, and at December 31, 2025, for commissions and reimbursements. Amounts due from these customers totaled \$1,995 at March 31, 2026, and at December 31, 2025. Customer deposits on hand from these customers totaled \$329,958 at March 31, 2026, and December 31, 2025, respectively. The loss of these customers would have a significant impact on the operations and cash flows of the Company.

The Company's supplier concentrations expose the Company to business risks, which the Company mitigates by attempting to diversify its supply chain. Significant supplier purchases, including inventory deposits, as a percentage of total inventory purchases are as follows:

	<u>THREE MONTHS ENDED MARCH 31,</u>	
	<u>2026</u>	<u>2025</u>
Supplier D	97%	0%

There were no amounts outstanding due this supplier at March 31, 2026, and December 31, 2025. The loss of key vendors may have a significant impact on the operations and cash flows of the Company.

The estimated fair value of financial instruments has been determined using available market information and appropriate valuation methodologies. However, considerable judgment is often required to interpret market data used to develop the estimates of fair value. Accordingly, the estimates presented may not be indicative of the amounts the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies could have a material effect on the estimated fair value amounts.

Disclosure of Fair Value

The disclosure requirements within Accounting Standards Codification (ASC) Topic 820-10, Fair Value Measurement, require disclosure of estimated fair values of certain financial instruments. For financial instruments recognized at fair value in the Company's statements of operations, the disclosure requirements of ASC Topic 820-10 also apply. The methods and assumptions are set forth below:

- Cash and cash equivalents are carried at cost, which approximates fair value.
- The carrying amounts of receivables approximate fair value due to their short-term maturities.
- The carrying amounts of payables approximate a fair value due to their short-term maturities.

Asset and liabilities measured and reported at fair value are classified and disclosed in one of the following categories based on inputs: Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 — Inputs other than quoted prices included within Level 1 are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 — Pricing inputs include significant unobservable inputs used in determining the fair value of investments. The types of investments which would generally be included in this category include equity securities issued by private entities.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the determination of which category within the fair value hierarchy is appropriate for any given investment is based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.

The Company's convertible promissory notes contain variable conversion provisions upon default, Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and shares to be issued were recorded as derivative liabilities on the default dates.

The following table presents changes during the three months ended March 31, 2026, in Level 3 liabilities measured at fair value on a recurring basis:

Fair value- December 31, 2025	\$ 442,430
Conversion of convertible promissory notes	-
Fair value- March 31, 2026	<u>\$ 442,430</u>

The levels of the fair value hierarchy into which the Company's assets and liabilities fall as of March 31, 2026, are as follows:

Liabilities	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Derivative liabilities – convertible promissory notes	\$ —	\$ —	\$ 443,430	\$ 442,430
Total fair value	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 442,430</u>	<u>\$ 442,430</u>

Inventories

Inventories are stated at the lower of cost or market. Cost is determined based on the first-in, first-out cost flow assumption (“FIFO”) while market is determined based upon the estimated net realizable value less an allowance for selling and distribution expenses and a normal gross profit. The Company evaluates the need for inventory reserves associated with obsolete, slow moving, and non-sellable inventory by reviewing estimated net realizable values on a periodic basis. As of March 31, 2026, and December 31, 2025, the Company believes there are no excess and obsolete inventories and accordingly, did not record an inventory reserve. Inventories consist of purchased finished goods.

Sales Taxes

Sales taxes for the three-month periods ended March 31, 2026 and 2025, were recorded on a net basis. Included in accrued expenses at both March 31, 2026, and December 31, 2025, is approximately \$61,000 related to sales taxes.

Warranty

The Company warrants the sale of most of its products and records an accrual for estimated future claims. The standard warranty is typically for a period of three years. Such accruals are based upon historical experience and management’s estimate of the level of future claims. The Company recorded a liability as of March 31, 2026, and December 31, 2025, of \$6,809 and \$7,782, respectively. The expense is included in cost of sales in the statements of operations and within accrued expenses on the accompanying balance sheets.

Lease Commitment

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Lease expense for variable lease components are recognized when the obligation is probable. Operating lease right of use (“ROU”) assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company’s lease, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.

Variable lease payments not dependent on a rate or index associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments are presented as operating expenses in the Company’s statement of operations in the same line as the expense arising from fixed lease payments. As of March 31, 2026 and December 31, 2025, management determined that there were no variable lease costs.

Net Loss per Share

Net earnings or loss per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding during the period, excluding shares subject to redemption or forfeiture. The Company presents basic and diluted net earnings or loss per share. Diluted net earnings or loss per share reflect the actual weighted average of common shares issued and outstanding during the period, adjusted for potentially dilutive securities outstanding. Potentially dilutive securities are excluded from the computation of the diluted net loss per share if their inclusion would be anti-dilutive. As all potentially dilutive securities are anti-dilutive as of March 31, 2026, and 2025, diluted net loss per share is the same as basic net loss per share for each period.

Conversion of outstanding warrants, certain accrued liabilities and convertible promissory notes/debt at March 31, 2026 may result in an estimated 5,817,023,533 additional shares of common stock outstanding. At March 31, 2026, 2025, there are 5,000,000,000 common shares authorized and 3,732,294,292 outstanding. Management has agreed to amend its shares authorized to meet the future requirements resulting from any of the above conversions.

NOTE 3. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of:

	March 31, 2026	December 31, 2025
Building	\$ —	\$ —
Tooling	149,705	149,705
Furniture and equipment	24,987	24,987
	174,692	174,692
Less: accumulated depreciation and amortization	(24,987)	(24,987)
	<u>\$ 149,705</u>	<u>\$ 149,705</u>

Depreciation and amortization expense related to property and equipment was \$0 for the three months ended March 31, 2026, and 2025.

NOTE 4. CONVERTIBLE NOTES PAYABLE

The aggregate of convertible promissory notes is as follows:

Convertible promissory notes	March 31, 2026	December 31, 2025
Principal balance	\$ 514,922	\$ 514,922
Debt discount balance	—	—
Net Notes balance	<u>\$ 514,922</u>	<u>\$ 514,922</u>

The Net Notes balance at March 31, 2026, is comprised of the following:

	Principal
March 2022	\$ 342,472
August 2022	48,750
June 2025	70,700
July 2025	53,000
	<u>\$ 514,922</u>

The Net Notes balance at December 31, 2025, is comprised of the following:

	Principal
March 2022	\$ 342,472
August 2022	48,750
June 2025	70,700
July 2025	53,000
	<u>\$ 514,922</u>

As of March 31, 2026, and December 31, 2025, and separately, the Company is in default of a matured convertible promissory note, issued to a lender on August 8, 2022, with principal and interest due in the amounts of \$48,750 and \$76,162, respectively as of March 31, 2026. The convertible note included a cross-default and a cross-default provision which required the Company to remit payment of principal, accrued interest, default interest, and legal fees, multiplied by 150%. The amount of approximately \$74,000 in default penalties has been accrued and is recorded in the Company's balance sheet as of March 31, 2026, and December 31, 2025, for this lender.

In June and July 2025, the Company issued convertible notes to a third party, totaling \$118,000 with original issue discounts of \$27,500. The notes each have six-month maturity dates and are due in December 2025 and January 2026. The notes bear interest at a rate of 12% per annum of which \$5,080 in interest expense has been recorded for the three-month period ended March 31, 2026. The convertible notes may be converted, at the option of the holder, into shares of the Company's common stock at terms specified in the note agreements. The original issue discount is being amortized over the term of each note using the effective interest method.

On December 1, 2025, the Company entered into a letter agreement with the holder of the notes to extend the maturity date until May 1, 2026, for the above notes. Per the letter agreement, the total amount due at December 1, 2025 includes a default penalty in the amount of \$45,670 and accrued interest through December 1, 2025, of \$6,330 for a total of \$170,000. The default penalty has been recorded as other expense in the Company's statement of operations for the year ended December 31, 2025. Interest will continue to accrue on the \$170,000 at the rate of 12% per annum. Certain conditions and events of default were waived as well but in certain instances only until May 1, 2026, if the notes are not repaid in full. As the Agreement was in default as of May 1, 2026, due to lack of payment as required, it became void and the notes remain outstanding and in default in their original principal amounts, plus a default interest rate, and a daily default fee. See Note 12.

NOTE 5. LOAN PAYABALE

In December 2025, the Company entered into a loan and security agreement (“Loan”) with a company for the amount of \$500,000 with a fixed interest payment and balloon payment due in full on April 1, 2026 (the “Maturity Date”). The loan has a fixed interest payment of \$100,000 due upon maturity. Interest expense totaled \$86,538 for the three months ended March 31, 2026.

The Loan is fully secured by all of the assets of the Company. As the Loan was not paid by the Maturity Date, a \$50,000 penalty has also been assessed against the Company. See Note 12.

While the Company has purchase orders and pending deposits, it is seeking to collect to repay the Loan, there is no assurance if and when it will do so and ultimately all of the assets could be subject to foreclosure and sale to repay the Loan.

NOTE 6. LONG-TERM DEBT

Government Debt

In June 2020, the Company received a \$150,000 economic injury disaster loan (“EIDL”). The loan accrues interest at a rate of 3.75% annually and is collateralized by all personal property and intangible assets of the Company. The loan has a 30-month moratorium on payments, after which monthly principal and interest payments of \$731 will be made through the maturity date of June 2050. Interest expense totaled \$1,387 and \$1,387 for the three months ended March 31, 2026 and March 31, 2025, respectively.

Receivables Purchase Agreement

In December 2024, the Company entered into a receivables purchase agreement in the amount of \$97,860. Funds totaling \$70,000 were advanced. The agreement requires weekly payments of \$1,737 through January 2026. Interest expense totaled \$11,315 and \$11,989 for the three months ended March 31, 2026, and March 31, 2025, respectively.

NOTE 7. DERIVATIVE LIABILITIES

There has been no change in derivative liabilities for the three months ended March 31, 2026.

NOTE 8. RELATED PARTY TRANSACTIONS

Effective July 15, 2023, the Company’s board of directors executed a resolution whereby the CEO’s salary shall be reduced from \$365,000 to \$265,000 per year, with unpaid sums being accrued on the books of the Company and subject to an option in favor of the CEO to elect to convert the unpaid sums into shares of Company common stock. Deferred salary totaling \$246,375 and \$221,375 has been recorded as of March 31, 2026, and December 31, 2025, respectively, and may be converted at any time into shares of the Company’s common stock at a discount of 25% of the market value on the date of conversion. In addition, the Company has recorded an accrued liability totaling \$155,056 and \$147,960 at March 31, 2026, and December 31, 2025, respectively, for unpaid salary related expense due the Company’s CEO.

Compensation totaling \$5,000 per month has been recorded for an employee as board of director fees for the three months ended March 31, 2026, and 2025. The Company has an accrued liability totaling \$165,500 and \$150,500 for the unpaid director’s fees due to the director at March 31, 2026, and December 31, 2025, respectively

NOTE 9. STOCKHOLDERS’ DEFICIT

NOTE 10. WARRANTS

The following table summarizes the information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable at both March 31, 2026, and December 31, 2025:

<u>Date Issued</u>	<u>Exercise Price</u>	<u>Number Outstanding</u>	<u>Expiration Date</u>
October 1, 2021	\$ 0.025	9,000,000	October 1, 2026
August 10, 2022	\$ 0.00102	3,336,843	August 10, 2027
September 29, 2022	\$ 0.00102	2,780,690	September 29, 2027
February 11, 2023	\$ 0.00102	500,000	February 11, 2028
		15,617,533	

NOTE 11. COMMITMENTS AND CONTINGENCIES

Commitments

The Company has entered into a product development agreement with remaining payments totaling approximately \$300,000. The agreement requires that approximately \$150,000 of the payments be made in conjunction with certain developmental milestones which the Company expects to meet over the next twelve months. The remainder is to be paid in conjunction with future new product

sales.

Contingencies

The Company is subject to various loss contingencies and assessments arising in the normal course of the business, some of which relate to litigation, claims, property taxes, and sales and use tax or goods and services tax assessments. The Company considers the likelihood of the loss or the incurrence of a liability, as well as its ability to reasonably estimate the amount of loss in determining loss contingencies and assessments. An estimated loss contingency or assessment is accrued when it is probable that a liability has been incurred, and the amount of loss can be reasonably estimated. Management regularly evaluates current information available to them to determine whether such accruals should be adjusted. Currently, there are no pending court actions, or arbitration claims filed against the company.

NOTE 12. SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date the financial statements were available to be issued and determined that, other than the transactions described above, no additional events have occurred that would require adjustment to or disclosure in the financial statements.

On April 1, 2026, the Company was in default on its loan payable for which the lender has assessed a \$50,000 penalty.

An Agreement for convertible notes payable was in default as of May 1, 2026, due to lack of payment as required. It became void and the notes remain outstanding and in default in their original principal amounts, plus a default interest rate, and a daily default fee.